inc hold pt increas estim price base
construct backlog growth maintain hold margin risk analyst tate sullivan cfa full summari
horizon technolog financ corpor hrzn buy pt portfolio growth strong pipelin plu fee
waiver rais pt reiter buy analyst michael diana full summari
inc buy pt soar past estim revis estim st industri
headwind follow return mid-cycl rate analyst jame jang full summari
industri incorpor buy pt maintain buy rate pt annual ep estim
y/i ep growth expect analyst tate sullivan cfa full summari
immutep limit immp buy pt advanc second merck collabor dose first patient
proteon inc prto buy pt catalyst approach month phase data vonapanitas like
risk/reward analyst jason mccarthi ph full summari
vertex pharmaceut incorpor hold data posit similar wait
inc buy pt first look result miss revenu guidanc ahead
consensu higher market pivot growth underway analyst alexand scharf cfa full summari
corpor event call maxim salesperson inform
custom inc cover diana ndr connecticut ceo jay sidhu wed
reneuron group plc rene cover mccarthi ndr nyc ceo olav hellebo cfo michael hunt
corp ndr dalla ceo sherif foda tue
cover sullivan ndr boston ceo scott salmir cfo anthoni scaglion
stealthga inc gass cover jang ndr nyc ceo harri vafia tue
genco ship trade ltd cover jang ndr chicago ceo john wobensmith cfo
navig hold ltd nvg cover jang group luncheon new york ceo david butter thu
pm et
tuanch limit tc cover jang ndr nyc cfo troy mao investor relat dana cheng wed
tuanch limit tc cover jang ndr boston cfo troy mao investor relat dana cheng thu
tuanch limit tc cover jang ndr chicago cfo troy mao investor relat dana cheng
tuanch limit tc cover jang ndr san francisco cfo troy mao investor relat dana cheng
tuanch limit tc cover jang ndr lo angel cfo troy mao investor relat dana cheng
cover jang ndr boston ceo gari vogel cfo frank decostanzo
director strategi busi develop costa tsoutsoplid tue apr
maxim group industri confer nyc mygr host sullivan wed
inc cover confer call cfo tonya robinson director
financi analysi michael bailen mon pm et
corpor ctrl cover chokshi ndr dalla cfo novakovich mon
inc stmp cover klee confer call cfo jeff carberri tue pm et
cover klee ndr chicago presid ceo michael prior cfo justin
cover klee ndr milwauke presid ceo michael prior cfo
inc cover klee ndr nyc ceo steve picket cfo ahlstrom tue apr
inc cover klee ndr boston ceo steve picket cfo ahlstrom wed apr
inc cover klee ndr chicago ceo steve picket cfo ahlstrom thu apr
annual silicon valley bu tour host chokshi tue jul
catalyst approach month phase data
vonapanitas like risk/reward
prto share trade sinc believ may
anticip data expect month
remind amend base result
see de-risk combin prior data fda feedback
current trial design unmet need space lead us see
trial miss primari endpoint primari unassist patenc
hit secondari patenc fistula use amend
base discuss fda aforement endpoint flip
secondari patenc fistula use co-primari total
data prior studi includ combin
success suffici file bla
valuat share price risen ahead data thu far valuat
opinion remain attract potenti transform
catalyst week away like risk/reward still risk
binari event recogn view may consid
aggress risk advers investor may choos step asid data come
de-risk studi reach statist
signific primari endpoint primari unassist patenc trial achiev
statist signific two key pre-specifi secondari endpoint secondari
patenc fistula use dialysi patient treat
vonapanitas achiev unassist use arterioven fistula avf vs
placebo base observ protocol
amend secondari patenc avf use hemodialysi co-primari
endpoint base manag talk fda endpoint clinic
import could support approv suffici posit data risk/reward
profil studi skew posit view increas power
trial patient vs top-line data expect march
potenti bla p-valu primari reach
need addit trial would consid support
defin endpoint primari unassist patenc time placement
fistula first thrombosi intervent maintain/restor blood flow
long need fix secondari patenc time abandon
includ censor event surgical/endovascular intervent long
complet fail fistula use hemodialysi success use fistula
w/adequ blood flow hemodialysi day job
market opportun analysi proteon present page nearli
fistula creat annual larg driven new hemodialysi
patient everi year radiocephal fistula space fall
medicar part initi target proteon assumpt
rel small sale forc rep suffici target
nephrologist surgeon price cost fistula abandon
complic like loss use infect go catheter etc cost
first year north year two three combin
compani disclos plan around price assum vonapanitas
fair factor model
click full note
maintain buy rate pt annual ep estim
y/i ep growth expect
maintain annual ep estim report oper
ep y/i estim
initi review result continu recommend
buy share expect energi effici project air
condit electr heat upgrad exist janitori servic
client increas margin ep growth
base part time start recogn incom energi
effici project within technic solut busi segment
maintain oper ep estim
note maintain guidanc oper ep
ep
may review estim earn confer call et
morn dial
bundl solut exist client help increas margin
effici project facil servic work maintain upgrad
electr mechan intern infrastructur insid multi-stori commerci
build type larg facil continu above-averag
margin view technic solut busi group also
continu higher growth busi segment
instanc even though first quarter fiscal year end octob usual
lower revenu growth quarter year-over-year revenu growth
technic solut busi segment highest
growth rate among busi segment also technic solut margin
increas prior year
meaning level margin improv technic solut believ
feder govern shutdown delay energi effici project
expect today et confer call provid background
energi effici project time opportun higher total revenu
growth may provid detail energi effici project time
account project today call separ revenu declin year-
over-year busi segment partli due usual lower revenu
growth first quarter fiscal year also client may
select lower-cost competitor may will accept
meaning lower margin re-bid contract due higher labor cost
may also talk opportun decreas overhead cost compani
complet largest acquisit histori septemb
slight increas margin help ep exceed consensu
revenu million slightli million consensu forecast
oper ep increas y/i
consensu forecast higher margin four six busi segment contribut
ep growth lower interest expens reduc debt
million prior year
custom concentr multipl end market higher margin
energi effici work acceler ep growth lead higher
stock price view price target base gaap
ep estim current pe valuat ep
forecast base expect margin growth sell energi
effici contract target pe multipl slight premium averag
multipl peer group includ busi servic compani
energi effici contractor base view competit
advantag offer energi effici work facil servic current
click full note
ahead consensu higher market pivot growth
yesterday market close report weaker-than-expect
result issu strong guidanc includ shipment growth
acceler gross margin expans
kona shipment deplet growth acceler y/i
expect lead way ramp market effort
earn confer call morn et
bottom line would continu buyer despit miss due
initi guidanc support expect signific revenu acceler
expect kona lead way deplet growth strengthen
toward end plan significantli ramp market effort
moreov expect compani recent complet breweri restructur well
increas util anheuser-busch inbev bud nr resourc drive
continu gross margin expans although oper incom rel flat
invest year expect increas sale
robust growth benefit earn futur year also make compani
attract bud make qualifi offer acquir
per share august
result summari revenu y/i estim
consensu shipment y/i wider
estim declin top-line also neg impact declin
revenue-per-barrel non-bud beer-rel shipment well lower brewpub
revenu gross margin y/i estim
adjust ebitda y/i estim
consensu loss per share ep
estim consensu see page detail
estim price growth bracket
estim impli net revenu growth roughli
net revenu bracket estim consensu
gross margin y/i bracket
estim consensu sg expens y/i
estim consensu effect tax rate
estim consensu final capit expenditur
bracket estim consensu
see page detail
balanc sheet updat decemb cash
equival balanc sheet drew
avail line credit america nr fund partner
brand acquisit cost also outstand term loan
outstand capit leas
compel valuat util seven-year dcf analysi weight
averag cost capit wacc termin growth rate deriv
price target moreov view attract valu compar
standpoint forward ev/revenu multipl peer averag
forward ev/ebitda multipl slightli peer averag
price target impli share trade forward revenu still
peer forward ebitda believ justifi compani ramp
market expenditur drive top-lin growth
click full note
soar past estim revis estim st
industri headwind follow return mid-cycl
rate
soar past expect revenu ebitda ep
forecast although consensu
revis estim estim lower due low
earn environ expect return black
rais estim
activ commerci manag strategi led multi-year high tce
rate per vessel/day conjunct strateg fleet
replenish program help increas quarterli tce compound-annual-growth-rate
sinc
report solid beat expect albeit
consensu top-lin result y/i result
net revenu vs maxim consensu
ebitda vs maxim consensu
oper ep vs maxim consensu
activ commerci manag strategi pay dividend
addit charter-in day help increas fleet tce rate per vessel/
day y/i chartered-in day help compani achiev
highest tce rate sinc continu outperform benchmark indic delta
per vessel/day strategi allow opportunist
add-in tonnag essenti oper separ symbiot asset-light model
increas overal earn potenti exploit arbitrag avail
cargo tonnag attribut out-performance vs indic
reduc near-term estim account industri headwind believ
number unresolv industri headwind unresolv -china trade
disput could limit dri bulk earn addit announc
day fix per vessel/day favor
rate per vessel/day still per vessel/day achiev
therefor look revenu prior
ebitda prior oper loss prior ep
estim lower earn profil due lower fulli
expect rebound start
rais estim expect strategi
help increas rate implement prove
strategi believ could pose opportun revenu expans
via chartered-in vessel therefor rais estim
expect revenu prior ebitda prior
oper ep prior
although expect macro headwind limit earn expect uplift
believ share under-valued report strong
result still trade forward analysi expect current
macro headwind challeng handymax segment dissip
 -china trade disput settl grain harvest season allow increas
util segment therefor maintain buy rate price target
price target base multipl midpoint forward
normal estim prior
click full note
portfolio growth strong pipelin plu fee
waiver rais pt reiter buy
hrzn nii per share includ incent fee waiver
versu dividend
anoth quarter portfolio growth transfer loan
joint ventur arena investor strong pipelin unfund loan
approv commit invest advisor waiv previous
defer incent fee hrzn well posit view
continu grow invest portfolio continu grow off-balance-
sheet joint ventur continu cover dividend nii
cover dividend without incent fee waiver
price target equat previous
in-line high-qual bdc view bdc hrzn
focu senior secur float rate loan also receiv warrant
non-accru deserv trade premium bdc
incom nii per share includ incent fee waiver versu
quarterli dividend ep due unreal loss
dividend slightli exceed ep net asset valu stabl
data hrzn yield invest portfolio versu
partli due incom liquid event strong origin size
hrzn invest portfolio increas would increas
hrzn transfer loan joint ventur jv arena investor
give jv critic mass access jv debt facil
credit qualiti hrzn loan non-accru decemb
unchang septemb
leverag larger portfolio leverag equiti
hrzn previou leverag target due legisl statutory/
regulatori leverag possibl approv sharehold octob
hrzn sharehold approv leverag limit
effect hrzn new leverag target rang equiti present hrzn
liquid new invest
ventur addit mean achiev higher leverag larger hold-siz
invest hrzn jv arena investor invest loan similar one
hrzn current make initi commit million equiti jv
arrang borrow initi million new york life insur compani
privat jv also leverag
maintain dividend estim per share rais ep
estim expect size jv doubl
least doubl dividend incom jv page updat
rais price target hrzn share current trade
new price target equat previous
in-line high-qual bdc view bdc hrzn focu
senior secur float rate loan also receiv warrant non-accru
deserv trade premium bdc
maintain buy rate next four quarter expect dividend
yield stock price appreci price target
result estim total return
click full note
data posit similar wait
vertex announc tripl combin tezacaftor tez
ivacaftor iva met primari endpoint improv lung function
dual trial program test homozyg
heterozyg het/min patient recal tripl
also posit week data
tripl vertex make decis file approv
indic
data posit similar data week mark
demonstr double-digit improv popul het/min
homozygot improv placebo
win right close call
vertex perspect good problem two tripl option
could eventu reach broader cf market
conclus news less expect view
reflect rel littl movement share data next
maintain hold rate base valuat
valuat tripl unlock cf popul patient
continu drive top-line growth assum reach approv concern remain
valuat believ success cf price current valuat
compani vertex also target gene edit therapi could applic
cf patient though still earli stage develop
yet factor model compani also pipelin outsid
cf includ antitrypsin defici pain sickl cell/-thal focal
segment glomerulosclerosi also earlier stage develop
head head homozygot
studi week demonstr improv
vs placebo improv arm placebo
arm ad on-going tez/iva regimen
studi week demonstr improv
vs placebo improv arm placebo
ad on-going tez/iva regimen
head head function heterozygot
studi week demonstr improv
vs placebo improv arm
placebo combin well toler safeti data patient
reach week patient reach week
studi week demonstr improv
vs placebo improv arm
placebo combin well toler includ patient
reach week time analysi patient reach week
click full note
advanc second merck collabor
immutep announc dose first patient basket
studi lead asset eftilagimod alpha efti merck
nr keytruda evalu combin pd-x nave refractori patient
lung head neck
studi enrol patient center across
us eu australia
recal keytruda approv set lung
 view keytruda like becom standard care
lung chemo keytruda combo approv base overal respons
rate vs chemo alon bar higher howev keytruda
monotherapi approv orr complet
respons cr rate
increment posit matur tacti-mel data present
world immunotherapi congress san diego result
part studi cohort total efti ad cycl
keytruda continu show durabl month previou
month report see note orr part
efti given cycl day keytruda orr also remain consist
treatment on-going month four patient
conclus checkpoint futur lay combin treatment
nr eoc pharma privat merck merck kgaa/pfiz nr four
oncolog space lend support program
efti keytruda patient unresect metastat melanoma
poor respons diseas progress keytruda monotherapi studi
fulli enrol final patient part recruit dose
treatment posit data part report earli posit
data part well durabl respons continu seen part
month vs month previous report overal respons rate
diseas control rate remain consist previou disclosur
